Amgen (AMGN) Finished Goods (2013 - 2017)

Amgen (AMGN) posted quarterly Finished Goods of $1.1 billion for Q2 2017, down 4.57% quarter-over-quarter from $1.2 billion in Q1 2017.

Amgen (AMGN) Finished Goods (2013 - 2017) Analysis & Trends

Amgen's Finished Goods history runs 5 years deep, the most recent figure standing at $1.1 billion for Q2 2017.

In Q2 2017, Finished Goods changed N/A year-over-year to $1.1 billion; the TTM figure through Jun 2017 stood at $1.1 billion (changed N/A YoY), while the FY2016 annual figure was $912.0 million, up 29.36% from the prior year.
Finished Goods for Q2 2017 stood at $1.1 billion, down from $1.2 billion in the prior quarter.
The five-year high for Finished Goods was $1.2 billion in Q1 2017, with the low at $705.0 million in Q4 2015.
The 5-year median for Finished Goods is $914.0 million (2014), against an average of $920.5 million.
The sharpest annual moves came in 2015 and 2017: Finished Goods decreased 21.49% in 2015, then soared 48.02% in 2017.
Amgen's Finished Goods stood at $738.0 million in 2013, then gained by 21.68% to $898.0 million in 2014, then slipped by 21.49% to $705.0 million in 2015, then gained by 29.36% to $912.0 million in 2016, then increased by 21.27% to $1.1 billion in 2017.
Business Quant data shows AMGN's Finished Goods at $1.1 billion in Q2 2017, $1.2 billion in Q1 2017, and $912.0 million in Q4 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Johnson & Johnson	652.89 Bn	632.13 Bn	17.26 Bn
2	AbbVie	470.43 Bn	463.86 Bn	12.70 Bn
3	Merck	375.74 Bn	368.60 Bn	12.21 Bn
4	Novartis Ag	302.99 Bn	295.30 Bn	11.24 Bn
5	Astrazeneca	257.51 Bn	252.61 Bn	12.86 Bn
6	Amgen	237.06 Bn	223.07 Bn	7.24 Bn
7	Gilead Sciences	182.88 Bn	179.70 Bn	6.22 Bn
8	Pfizer	160.14 Bn	148.44 Bn	10.94 Bn
9	Gsk	106.08 Bn	101.91 Bn	8.24 Bn
10	Sanofi	55.21 Bn	47.83 Bn	10.79 Bn

Download Data